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Aims: To assess the associations between baseline glucose-lowering agents (GLA) and cardiorenal 
outcomes with dapagliflozin vs. placebo in the DECLARE-TIMI 58 study. 
Methods: DECLARE-TIMI 58 assessed the cardiorenal outcomes of dapagliflozin vs. placebo in patients 
with type 2 diabetes. This post-hoc analysis elaborates the efficacy and safety outcomes by baseline GLA 
for treatment effect and GLA-based treatment interaction. 
Results: At baseline 14,068 patients (82.0%) used metformin, 7322 (42.7%) sulfonylureas, 2888 (16.8%) 
DPP-4 inhibitors, 750 (4.4%) GLP-1 receptor agonists (GLP-1 RA) and 7013 (40.9%) insulin. Dapagliflozin 
reduced the composite of cardiovascular death and hospitalization for heart failure (CVD/HHF) vs. 
placebo regardless of baseline GLA, with greater benefit in the small group of patients with baseline use 
of GLP-1 RA (HR [95% CI] 0.37[0.18, 0.78] vs. 0.86[0.75,0.98] in GLP-1 RA users vs. non-users, 
pinteraction=0.03). The overall HR for major adverse cardiovascular events (CVD, myocardial infarction or 
ischemic stroke) was 0.93 (95% CI 0.84,1.03) with dapagliflozin vs placebo, with no interaction by 
baseline GLA (pinteraction >0.05). The renal specific outcome was reduced with dapagliflozin vs. placebo in 
the overall cohort (HR [95%CI] 0.53[0.43-0.66]), with no interaction by baseline GLA (pinteraction >0.05). All 
of these outcomes were similar in those with vs. without baseline metformin use.  
Conclusions: The effects of dapagliflozin on cardiorenal outcomes were generally consistent regardless 
of baseline GLA, with consistent benefits regardless of baseline metformin use.  The potential clinical 
benefit of combining SGLT-2 inhibitors with GLP-1 RA, given some evidence of cardiovascular risk 
reduction with both classes, should be further explored. 
  
  




Global prevalence of type 2 diabetes mellitus (T2DM) is steadily increasing and the number of people 
living with diabetes in 2019 has been estimated to be 463 million (1). The two recent decades have seen 
marked advancements in diabetes care with the inclusion of GLP-1 receptor agonists (GLP-1 RA), di-
peptidyl-peptidase-4 (DPP-4) inhibitors and sodium glucose co-transporter 2 (SGLT-2) inhibitors in the 
treatment armamentarium of type 2 diabetes (2). In contrast to sulfonylureas or insulin, these agents do 
not lead to hypoglycemia or weight gain, and SGLT-2 inhibitors and GLP-1 RA in fact lead to weight loss 
(2). Cardiovascular outcome trials (CVOT) with DPP-4 inhibitors demonstrated no cardiovascular benefit, 
yet, more recent trials of SGLT-2 inhibitors and GLP-1 RA demonstrated marked cardiovascular and renal 
benefits – albeit with some heterogeneity within each class (3-7). Moreover, while a recent meta-
analysis indicated the magnitude of benefit on major adverse cardiovascular events (MACE) was overall 
similar with GLP-1 RA and SGLT-2 inhibitors (HR 0.88, 95% CI 0.82-0.94 for both drug classes), effects on 
hospitalization for heart failure (HHF) and adverse renal outcomes differed markedly, with a more 
pronounced reduction observed with SGLT-2 inhibitors (5). Whether combining these two drug classes 
yields additive or synergistic cardiorenal outcomes is yet unclear and has been the focus of several 
observational and post-hoc analyses (8-11). 
The vast majority of patients included in the CVOTs conducted over the last decade were not treatment 
naïve and had been taking at least one glucose lowering agent (GLA) at baseline. In the earlier trials, 
these consisted mostly of metformin, sulfonylureas and insulin, whereas in the more recent 
Dapagliflozin Effect on Cardiovascular Events (DECLARE) – TIMI 58 trial, incretin-based therapies (DPP-4 
inhibitors and GLP-1 RA) were used as well (12, 13).  While metformin is generally positioned as 
standard of care first line treatment for patients with T2DM, recent guidelines have challenged its 
status, due to lower quality of evidence supporting its cardio-protective role (14). The high prevalence of 
baseline metformin users in CVOTs of GLP-1 RA or SGLT-2 inhibitors argues against this approach, as the 
benefits observed were in a population with high background metformin use. Thus, it is clearly of 
interest to assess cardiorenal outcomes in patients with vs. without baseline metformin use (15, 16).   
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In these post-hoc analyses of the DECLARE-TIMI 58 trial, we assessed the associations between baseline 
GLA and cardiorenal outcomes.   
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MATERIALS AND METHODS 
Study overview 
In the DECLARE - TIMI 58 trial, a total of 17,160 patients, including 6,974 with established atherosclerotic 
cardiovascular disease (ASCVD) and 10,186 with multiple risk factors (MRF) but without ASCVD, were 
randomly assigned to receive dapagliflozin 10 mg daily or placebo and followed for a median of 4.2 
years. All patients were treated according to regional standards of care for cardiovascular risk factors - 
blood pressure, lipids, antithrombotic treatment and HbA1c. The design, baseline characteristics and 
principal results of this study have been previously published (12, 13, 17).   
 
Assessment of outcomes 
The dual composite efficacy endpoints were cardiovascular death or hospitalization for heart failure 
(CVD/HHF) and major adverse cardiovascular events (MACE; the composite of cardiovascular death, 
myocardial infarction [MI] or ischemic stroke). Additional prespecified efficacy outcomes included a 
renal specific composite outcome (sustained decrease of 40% or more in estimated glomerular filtration 
rate [eGFR] to less than 60 ml/min/1.73m2, new end-stage renal disease [ESRD], or death from renal 
causes), and the individual components of the primary endpoints. New onset confirmed sustained 
albuminuria was defined as the development of micro- or macro- albuminuria in people with 
normoalbuminuria at baseline which was observed over two consecutive visits at least 4 weeks apart. 
 
Statistical analysis 
Baseline characteristics are reported as frequencies and percentages for categorical variables and as 
mean and standard deviation (SD), or median and interquartile range (IQR) for continuous variables. 
Analyses were performed on an intention-to-treat basis. Within each subgroup, we calculated the effect 
of dapagliflozin on the incidence of the efficacy outcome using Cox regression models.  
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To test for heterogeneity of efficacy, hazard ratios (HRs) and 95% confidence intervals (CI) were 
determined from Cox regression models with stratification factor (ASCVD or MRF status and baseline 
hematuria) as strata in models comparing treatment in baseline GLA groups with formal statistical 
testing for interaction. Of note, due to a numerical imbalance in the early development program of 
dapagliflozin regarding bladder cancer events, all patients were screened for hematuria at trial entry, 
and patients in whom bladder cancer could not be ruled out were excluded from the study.  
To increase the robustness of our findings, multivariate analyses were conducted for each outcome and 
baseline GLA adjusting for baseline differences within each GLA. Baseline insulin subgroup was adjusted 
for baseline BMI, eGFR (CKD-EPI), diabetes duration, HbA1c, ASCVD vs. MRF, history of heart failure, 
history of myocardial infarction and all other baseline GLA. Baseline metformin was adjusted for 
baseline age, sex, baseline BMI, eGFR (CKD-EPI), ASCVD vs. MRF, diabetes duration, HbA1c, history of 
heart failure, history of MI, and all other baseline GLA. Baseline sulfonylureas subgroup was adjusted for 
baseline BMI, eGFR (CKD-EPI), diabetes duration, ASCVD vs. MRF, history of MI, and all other baseline 
GLA. Baseline DPP-4 inhibitors subgroup was adjusted for sex, baseline BMI, UACR, eGFR (CKD-EPI), 
diabetes duration, HbA1c, history of heart failure, history of MI, and all other baseline GLA. Baseline 
GLP-1 RA was adjusted for baseline BMI, age, sex, diabetes duration, history of heart failure, and all 
other baseline GLA.  
As a sensitivity analysis, we considered all outcomes by the use of each GLA at any time during the trial 
(defined as “ever” vs. “never” users).  
Mixed models for repeated measures in HbA1c, weight, systolic blood pressure (SBP), eGFR and UACR 
were analyzed to produce least-squares mean estimates and 95% CIs in each treatment and baseline 
GLA group. Three-way interactions were calculated assessing the interaction of baseline GLA status, visit 
and treatment allocation to dapagliflozin vs. placebo.  
This study should be considered as hypothesis generating, and there was no statistical adjustment for 
multiple comparisons. A p-value <0.05 was considered statistically significant. 
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All analyses were performed using SAS software, version 9.4 (SAS Institute Inc., Cary, NC, USA) and Stata 
version 14.2 (College Station, TX, USA).  
 
  





In the DECLARE-TIMI 58 trial, metformin was used by 14068 (82.0%) of the patients, sulfonylureas by 
7322 (42.7%), DPP-4 inhibitors by 2888 (16.8%), GLP-1 RA by 750 (4.4%) and insulin by 7013 (40.9%) of 
the patients at baseline. Baseline characteristics of patients by medication use are shown in 
supplementary tables 1A-E. As expected, multiple differences were noted when comparing baseline 
users vs. non-users of each drug class. In short, patients using metformin or GLP-1 RA were younger 
than non-users. HbA1c levels were higher with baseline insulin or sulfonylurea use vs. non-use whereas 
metformin or DPP-4 inhibitors were associated with lower baseline HbA1c levels compared with non-
users. Body mass index (BMI) was markedly higher in patients with baseline use of GLP-1 RA (35.4±6.8 
kg/m2) vs. those without GLP-1 RA use at baseline (31.9±5.9 kg/m2). Baseline eGFR levels were lower in 
insulin users yet higher in metformin or sulfonylureas users. Use vs. non-use of DPP-4 inhibitors was 
associated with lower levels of urinary albumin creatinine ratio (UACR) and insulin users had higher 
UACR compared with non-users. Patients with baseline insulin use had longer disease duration and 
higher prevalence of established cardiovascular disease or prior myocardial infarction (MI) compared 
with non-users, while opposite trends were observed with baseline use of metformin or sulfonylureas.  
 
Cardiovascular outcomes 
Dapagliflozin reduced the composite of CVD/HHF (HR [95% CI] 0.83 [0.73, 0.95]) regardless of baseline 
GLA (interaction p-values >0.05), though the effect appeared to be particularly large in the small group 
of patients with baseline use of GLP-1 RA (interaction p-value 0.03; Figure 1A). This was driven by a 
marked reduction in HHF in patients with baseline use of GLP-1 RA (HR 0.2 (95% CI 0.07, 0.60), Figure 
1B). These effects were not observed in analysis by use of GLP-1 RA at any time during the study, 
whereby the HRs for CVD/HHF and for HHF in GLP-1 RA users were in line with those seen in the overall 
study population, and no interaction was observed between use or non-use of GLP-1 RA during the trial 
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and reduction in CVD/HHF and in HHF with dapagliflozin vs. placebo (interaction p-values >0.05; 
supplementary figures 1A-B).  
The overall HR for MACE was 0.93 (95% CI 0.84, 1.03) with dapagliflozin vs placebo, and this was consistent 
regardless of the different GLA used at baseline (figure 2). A tendency toward greater benefit with 
dapagliflozin was observed in baseline insulin users (interaction p-value 0.06), yet not in those using insulin 
at any time during the study (interaction p-value 0.28, supplementary figure 1C).  
The individual components of MACE (CVD, myocardial infarction, ischemic stroke) and all-cause 
mortality with dapagliflozin vs. placebo are shown in supplementary figures 2A-H for baseline GLA use 
and by use of GLA at any time during the trial. Generally, these outcomes were balanced in the overall 
study population and consistently by GLA subgroups.   
Adjustment of all outcomes for baseline characteristics maintained these results (supplementary tables 2A-
G). Moreover, baseline number of GLA used revealed consistent outcomes as in the overall population (i.e. 
reduction of CVD/HHF and HHF with dapagliflozin vs. placebo and balanced for MACE and its components, 
supplementary table 3). 
 
Renal outcomes 
The prespecified composite renal specific outcome was reduced with dapagliflozin vs placebo in the 
overall study population (HR [95% CI] 0.53 [0.43, 0.66]) with no interaction by baseline GLA (interaction 
p values >0.05; Figure 3). New onset albuminuria (confirmed sustained) in patients without albuminuria 
at baseline was reduced with dapagliflozin vs. placebo (HR [95% CI] 0.79 [0.72, 0.87]) regardless of 
baseline GLA (interaction p values >0.05; Figure 4). Adjustment of these two outcomes for baseline 
characteristics maintained these results (Supplementary table 2H-I). These observations were consistent 
regardless of the number of baseline GLA used (interaction p values >0.05; supplementary table 3).  
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The overall pattern of eGFR changes with dapagliflozin vs. placebo throughout the trial was consistent 
across all baseline GLA. There was no interaction between treatment, visit, and use or non-use of each 
GLA at baseline (p>0.05 for all GLA). An initial decline in eGFR was observed with dapagliflozin vs. 
placebo with subsequent stabilization of levels, and final eGFR levels at month 48 were generally higher 
with dapagliflozin vs. placebo (Table 1, supplementary figure 3A). UACR levels were also generally lower 




There was greater decline in HbA1c, weight and systolic blood pressure with dapagliflozin vs. placebo 
across all subgroups of GLA with all parameters significantly lower with dapagliflozin at month 48 (Table 
1, supplementary figures 3B-D).  
 
DISCUSSION 
The current analyses of the DECLARE-TIMI 58 trial demonstrate overall consistent cardiovascular, renal 
and metabolic benefits with dapagliflozin vs. placebo regardless of type or number of baseline GLA. 
Cardiorenal outcomes did not differ irrespective of baseline use of metformin. CVD/HHF was more 
prominently reduced with dapagliflozin vs. placebo in the small subset of patients who used GLP-1 RA at 
baseline compared with those who did not, yet the magnitude of CVD/HHF reduction with dapagliflozin 
was similar when comparing those using vs. not using GLP-1 RA at any time during the study. Adverse 
renal outcomes were less frequent with dapagliflozin vs. placebo regardless of baseline GLA, moreover, 
new onset albuminuria was less frequent with dapagliflozin consistently across all subgroups assessed.  
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In our study, 3092 patients were not using metformin at baseline. This population was older, with longer 
standing diabetes and a higher prevalence of cardiovascular disease, CHF and chronic kidney disease 
compared with metformin users. Nevertheless, the impact of dapagliflozin on the cardiovascular, renal 
and metabolic outcomes of this cohort did not significantly differ from its effect in patients who had 
been using metformin at baseline. This observation persisted after adjusting for baseline characteristics. 
These data support the notion that the beneficial effect of dapagliflozin is consistent irrespective of 
baseline metformin use. Notably, analysis of data from the EMPA-REG OUTCOME trial also did not 
reveal heterogeneity of cardiovascular outcomes by baseline use vs. non-use of metformin (18). Thus, 
the role of metformin as first line treatment is further challenged, whereas early treatment with an 
SGLT-2 inhibitor may be a better therapeutic choice for many patients.   
Current treatment algorithms promote the early use of SGLT-2 inhibitors or GLP-1 RA in the care of 
patients with T2DM with or at high risk for atherosclerotic cardiovascular disease (2,14). The 
cardiometabolic benefits of combining GLP-1 RA and SGLT-2 inhibitors have been assessed in several 
trials demonstrating further improvement in cardiometabolic parameters when intensifying therapy 
with one class in addition to the other (19-24). Post-hoc analysis of the CANVAS program revealed a 
greater reduction of HbA1c, systolic blood pressure and body weight with canagliflozin vs. placebo in 
patients with baseline use of GLP-1 RA compared to those without (24).  
Combined use of GLP-1 RA and SGLT-2 inhibitors is advocated in patients at high CV risk, if HbA1c 
remains above target, yet the cardiorenal outcomes of this combination require further study (9, 10). 
Post-hoc analysis of the CANVAS program noted a similar effect of canagliflozin on the primary 
cardiovascular outcome and the composite adverse renal outcome in those with vs. without baseline 
use of GLP-1 RA (24). Observational real world data analysis with propensity score matching of patients 
using GLP-1 RA who added SGLT-2 inhibitors vs. sulfonylureas demonstrated reduced cardiovascular 
events and hospitalization for heart failure in those adding SGLT-2 inhibitors (8). Our study enrolled a 
significant number of patients with baseline use of incretin-based therapies, to an SGLT-2 inhibitor vs. 
placebo and thus enables analyses of the cardio-renal outcomes of this treatment combination.  
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All DPP-4 inhibitors have been neutral with respect to MACE, while a reduction in MACE has been 
demonstrated with most GLP-1 RA (liraglutide, semaglutide, albiglutide and dulaglutide), and within the 
SGLT-2 inhibitors class it had been shown for canagliflozin and empagliflozin yet did not reach statistical 
significance with dapagliflozin or ertugliflozin (5, 25). In our study, treatment with dapagliflozin vs. 
placebo did not significantly reduce MACE irrespective of baseline use of DPP-4 inhibitors or GLP-1 RA.  
Most DPP-4 inhibitors are neutral with respect to HHF, although a significant increased risk has been 
observed with saxagliptin (3). GLP-1 RA have been shown to have a modest benefit on reducing HHF, 
with a HR of 0.91 (0.84–1.00) in a recently published meta-analysis, albeit reduced HHF was not 
observed in the individual studies (5). To the contrary, SGLT-2 inhibitors have an established benefit in 
reducing HHF and current guidelines and consensus society recommendations, as well as drug product 
labeling, promote the use of dapagliflozin for the prevention of HHF in patients with T2DM with risk 
factors for or established atherosclerotic cardiovascular disease (2, 6, 14, 26).  Results from the present 
analyses suggest greater benefit with the combined use of GLP-1 RA and dapagliflozin regarding 
CVD/HHF, implying a possible synergistic effect. However, the number of evaluable events are small 
(only 34 events of CVD/HHF among baseline GLP-1 RA users), confidence intervals are wide, and this 
observation did not persist when analyzing by use of GLP-1 RA at any time during the trial implying this 
may be a chance observation.  
Our analyses further clarify the long-term renal outcomes of combining of SGLT-2 inhibitors – a class 
with established robust renal benefits, with incretin based therapies – which have also shown some 
favorable renal outcomes. DPP-4 inhibitors have been shown to reduce albuminuria in most but not all 
studies, with no effect on eGFR (27-30). GLP-1 RA have shown a larger and more consistent effect on 
albuminuria compared to DPP-4 inhibitors, and a slowing of eGFR decline has been demonstrated with 
dulaglutide and liraglutide in patients with eGFR<60 ml/min/1.73m2 (31-32). Dulaglutide has also 
demonstrated reduced rates of eGFR decline by ≥40% or ≥50% compared to placebo (33). The renal 
benefits observed with incretin based therapies, particularly GLP-1 RA have been attributed to anti-
inflammatory effects, alteration of renal hemodynamics due to inhibition of sodium reabsorption as well 
as effects secondary to weight loss, improved glycemic control and reduced blood pressure (10). SGLT-2 
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inhibitors convey renal protection by multiple mechanisms including alteration of renal hemodynamics 
and restoration of tubulo-glomerular feedback, reduction in tubular workload and metabolic stress and 
reduced blood pressure, weight, glucose and vascular stiffness (34-36). Many of the reno-protective 
effects of incretin based therapies and SGLT-2 inhibitors are probably complementary and therefore an 
added benefit of dapagliflozin on top of these agents may be expected (10).   
In our cohort, patients using DPP-4 inhibitors at baseline had lower levels of albuminuria compared with 
non-users. Whether this is reflective of other baseline characteristics or of the drug itself cannot be 
determined from these analyses. Nevertheless, the renal benefits of dapagliflozin occurred irrespective 
of baseline DPP-4 inhibitors use indicating an added renal benefit of prescribing dapagliflozin on top of 
DPP-4 inhibitors, though probably not a synergistic effect. Adding dapagliflozin to patients using GLP-1 
RA maintained the renal benefits observed in the overall DECLARE-TIMI 58 study population, with lower 
rates of the renal specific endpoint and of new onset albuminuria, and lower UACR at month 48. 
Although differences in the renal outcomes did not reach statistical significance in the small group of 
GLP-1 RA users, the trends were similar with no heterogeneity by GLP-1 RA use. Thus, the benefit of 
dapagliflozin was not altered by baseline GLP-1 RA use, promoting their combined use in renal 
protection.  
Patients using insulin at baseline experienced lower rates of MACE with dapagliflozin vs. placebo (HR 
[95% CI] 0.84 [0.74, 0.97]), yet this was not observed in patients not using insulin at baseline (interaction 
p-value 0.06). Notably, insulin users were more likely to have prior MI and longer disease duration – 
both of which we have previously demonstrated to be associated with reduced rates of MACE with 
dapagliflozin vs. placebo (37, 38). Thus, it may be possible that patient characteristics and not insulin use 
in itself underlie this observation. Moreover, analysis by use of insulin at any time during the trial did not 
demonstrate a differential effect on MACE of dapagliflozin vs. placebo by insulin use.  
Dapagliflozin led to greater decline in HbA1c, weight and SBP and compared to placebo. These changes 
were largely unaffected by baseline GLA in line with previously published data, further supporting the 
favorable metabolic impact of adding dapagliflozin to any prevailing glucose-lowering regimen (39). The 
This article is protected by copyright. All rights reserved.
 
 
addition of dapagliflozin to patients with vs. without baseline use of incretin based GLA led to 
comparable HbA1c reductions (Table 1, supplementary figure 3B), in line with data from most studies 
demonstrating the glycemic efficacy of this combination (19-23).  
Some limitations of our analyses should be noted. First, while analyses by baseline GLA were generally 
pre-specified, the specific analytic plan as well as analysis of the metabolic outcomes were largely post-
hoc. Second, baseline use or non-use of a particular GLA may have been determined by local guidelines, 
cost, availability of treatment or patient preference and not by true biological variation and the results 
should thus be interpreted in this context. Moreover, the impact of this confounder is even more 
substantial in the sensitivity analyses by medication use at any time during the study. This post-
randomization analysis may be affected by treatment allocation as well and thus is more subject to 
potential bias than the primary one by baseline medications. Third, we did not account for the particular 
agents used within each class or for drug dosages. Finally, no correction for multiplicity was performed, 
thus although some of the interaction p-values were indeed <0.05 these must be considered as 
hypothesis generating alone.   
In conclusion, in this study, the cardiovascular and renal benefits of dapagliflozin were observed 
regardless of baseline GLA. Benefit is maintained, when combining classes of CV and renal protecting 
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LEGENDS TO FIGURES 
Figure 1A – CVD/HHF with dapagliflozin vs. placebo by baseline glucose lowering agents 
Figure 1B – HHF with dapagliflozin vs. placebo by baseline glucose lowering agents 
Figure 2 – Major adverse cardiovascular events with dapagliflozin vs. placebo by baseline glucose 
lowering agents 
Figure 3 – Renal specific outcome with dapagliflozin vs. placebo by baseline glucose lowering agents 
Legend: The renal specific outcome was a composite of: sustained decrease of 40% or more in eGFR to 
less than 60 ml/min/1.73m2, new end-stage renal disease, or death from renal causes 
Figure 4 – New onset albuminuria with dapagliflozin vs. placebo by baseline glucose lowering agents 
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Table 1 – Metabolic parameters at 48 months with dapagliflozin and placebo by baseline glucose lowering agent 
Baseline glucose 
lowering agent 
HbA1c (%) Weight (kg) SBP (mmHg) eGFR UACR 
DAPA PBO DAPA PBO DAPA PBO DAPA PBO DAPA PBO 
Metformin 
YES 7.83±0.02* 8.08±0.02 86.73±0.08* 88.77±0.08 132.51±0.21* 135.03±0.21 77.61±0.18* 75.80±0.18 128.74±6.33* 185.42±6.42 
NO 7.95±0.04+ 8.14±0.04 88.17±0.20* 89.58±0.21 132.26±0.47+ 133.97±0.49 73.45±0.40 72.67±0.41 170.99±16.38 195.12±16.77 
SUR 
YES 7.90±0.03* 8.17±0.03 84.36±0.11* 86.46±0.11 131.67±0.29* 134.71±0.29 78.01±0.25* 76.38±0.25 111.37±8.45* 161.41±8.49 
NO 7.82±0.02* 8.03±0.02 88.96±0.11* 90.77±0.11 133.06±0.26* 134.94±0.26 76.03±0.22* 74.39±0.23 153.23±7.22* 200.25±7.39 
DPP-4 i 
YES 7.84±0.04+ 8.02±0.04 85.65±0.15* 88.14±0.15 130.36±0.45* 133.57±0.46 77.87±0.38* 75.75±0.38  101.89±10.01 126.81±10.08 
NO 7.86±0.02* 8.11±0.02 87.22±0.07* 89.07±0.07 132.91±0.21* 135.11±0.22 76.69±0.18* 75.15±0.19 140.49±6.73* 195.71±6.87 
GLP-1 RA 
YES 7.93±0.08¶ 8.19±0.09 99.44±0.46¶ 100.97±0.50 131.11±0.87¶ 133.72±0.94 78.04±0.76 76.14±0.82 106.00±23.16¶ 178.02±25.08 
NO 7.85±0.02* 8.09±0.02 86.39±0.07* 88.36±0.07 132.54±0.19* 134.90±0.20 76.83±0.17* 75.22±0.17 138.63±13.84¶ 181.79±13.92 
Insulin 
YES 8.07±0.03* 8.35±0.03 90.89±0.13* 92.85±0.14 133.10±0.31* 135.50±0.32 74.44±0.26* 72.81±0.27 162.97±31.28 232.56±32.04 
NO 7.70±0.02* 7.92±0.02 84.33±0.08* 86.25±0.08 132.04±0.24* 134.41±0.24 78.54±0.21* 76.88±0.21 111.37±6.93+ 145.17±6.97 
 
Values are mean ± SE. *p<0.0001, +p<0.01, ¶p<0.05 for dapagliflozin vs. placebo. eGFR – estimated glomerular filtration rate; SBP – Systolic blood 
pressure; SUR – sulfonylureas; UACR – urinary albumin creatinine ratio  
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Figure 2 – Major adverse cardiovascular events with dapagliflozin vs. placebo by baseline glucose 
lowering agents 
  
This article is protected by copyright. All rights reserved.
 
 
Figure 3 – Renal specific outcome with dapagliflozin vs. placebo by baseline glucose lowering agents 
 
The renal specific outcome was a composite of: sustained decrease of 40% or more in eGFR to less than 
60 ml/min/1.73m2, new end-stage renal disease, or death from renal causes 
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Figure 4 – New onset albuminuria with dapagliflozin vs. placebo by baseline glucose lowering agents 
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